Gastroenterology
Commentary
New and emerging options for treating recurrent C. difficile
I’m pleased to say that newer fecal microbiota products are coming in fast and furious.
News from the FDA/CDC
FDA clears AI-assisted colonoscopy device
The device helps identify lesions in real time and is associated with a significant increase in the adenoma detection rate.
Conference Coverage
Chronic constipation linked to cognitive decline
“These results stress the importance of clinicians discussing gut health, especially constipation, with their older patients.”
Feature
Humira biosimilars: Five things to know
The launch of eight adalimumab biosimilars so far in 2023 ended Humira’s 20-year monopoly, but it’s not clear yet if these discounted drugs will...
Latest News
Higher alcohol consumption linked to early-onset CRC
Compared with light drinking, moderate and heavy drinking were associated with a significantly elevated risk of early-onset CRC.
Latest News
GLP-1 agonists offer multiple benefits in type 2 diabetes with liver cirrhosis
“GLP-1 RAs may be a treatment option for diabetes patients with liver cirrhosis,” but additional studies are needed to confirm the results, the...
Conference Coverage
Survodutide impresses in phase 2 weight loss trial
Survodutide has received U.S. Food and Drug Administration Fast Track Designation for adults with NASH.
From the Journals
Is there a link between esophageal risk and sleep habits?
Too much or too little sleep, daytime naps, and other sleep patterns may increase the risk of developing esophageal cancer.
Latest News
FDA OKs Suflave, a lower-volume colonoscopy prep drink
Most patients reported that Suflave was “tolerable to very easy” to consume and indicated they would request it for a subsequent colonoscopy.
Latest News
WHO plans to declare common sweetener as possible carcinogen
Aspartame would join the “possibly” carcinogenic group, which includes gasoline engine exhaust and working as a dry cleaner.
Feature
Does colchicine have a role in treating excess ASCVD risk in patients with chronic inflammatory conditions?
Experts in rheumatology, dermatology, and gastroenterology assess the potential of colchicine 0.5 mg to treat residual risk for atherosclerotic...